Featured Editorial

  1. How The Strait Of Hormuz Crisis Is Stalling U.S. Medical Breakthroughs 4/7/2026

    Global shipping disruptions through the Strait of Hormuz are delaying investigational drugs, increasing costs, and threatening the timeline of critical U.S. clinical trials.

  2. The Hidden Bottleneck: Clinical Supply Strategy In Study Start-Up 4/7/2026

    Delays in clinical trials often hide in late supply planning. Early integration of supply strategy ensures product availability, reduces risk, and keeps studies on schedule.

  3. Why More Tools Won't Fix Clinical Supply 4/6/2026

    Clinical supply fails when tools outpace the operating model. Clear workflows, governance, trusted records, and adoption strategies create scalable, reliable supply.

  4. The Hidden Supply Chain Risks That Can Derail Small Biotech Trials 4/3/2026

    Small biotech trials face hidden supply risks that waste up to 75% of materials, delay timelines, and drain funding faster. Learn what causes them and how to prevent them.

  5. What's Breaking In Clinical Trial Supply — And How To Fix It 4/2/2026

    Clinical trial supply often stalls programs. Explore why forecasting, packaging, and global logistics fail and how to keep trials on track and on time.

  6. R&D Capitalization Decisions That Drive Clinical Trial Supply 4/1/2026

    R&D capitalization changes are reshaping trial funding. The real impact hits clinical supply, where tax strategy now directly influences timelines, inventory, and execution.

  7. The RTSM–EDC Integration Trap: Why Broken Workflows Still Undermine Trial Execution 3/31/2026

    Broken RTSM–EDC integrations keep clinical trials stalled with blocked randomizations, kit errors, and endless reconciliations. Here’s how to fix workflows before tech fails.

  8. Building Win-Win Partnerships In Clinical Trial Supply 3/30/2026

    Strong supplier partnerships are the backbone of reliable clinical trial supply, driving speed, flexibility, and better outcomes through trust, transparency, and shared goals.

  9. The NDC-12 Ripple Effect: Why Clinical Trial Supply Chains Must Act Seven Years Early 3/30/2026

    Clinical trial supply chains face a 2033 NDC-12 deadline; early action on product identity, labeling, and data governance can prevent costly disruptions and misalignment.

  10. Bridging Preclinical Science And Trial Supply Success 3/27/2026

    Bridging preclinical science and clinical supply ensures therapies reach patients efficiently. Early planning, collaboration, and flexible supply chains prevent costly delays.